Wall Street analysts expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report $5.16 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $2.91 million and the highest is $7.84 million. BioCryst Pharmaceuticals posted sales of $7.76 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.5%. The firm is scheduled to announce its next quarterly earnings results on Monday, November 6th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $5.16 million for the current year, with estimates ranging from $18.36 million to $29.58 million. For the next fiscal year, analysts expect that the company will report sales of $24.56 million per share, with estimates ranging from $14.35 million to $34.66 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. During the same period in the prior year, the business earned ($0.22) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was down 35.4% on a year-over-year basis.
BCRX has been the subject of several analyst reports. Jefferies Group LLC upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $5.00 to $7.00 in a research report on Wednesday, September 6th. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Wednesday, August 9th. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. Finally, ValuEngine upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and an average target price of $8.78.
COPYRIGHT VIOLATION WARNING: “$5.16 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/10/13/5-16-million-in-sales-expected-for-biocryst-pharmaceuticals-inc-bcrx-this-quarter-2.html.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) remained flat at $5.19 during midday trading on Monday. The company’s stock had a trading volume of 1,121,264 shares. The firm’s market capitalization is $417.42 million. BioCryst Pharmaceuticals has a 1-year low of $3.75 and a 1-year high of $9.25. The firm has a 50-day moving average price of $5.22 and a 200 day moving average price of $5.69.
In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 0.3% in the 1st quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares during the period. ProShare Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals by 0.9% in the 2nd quarter. ProShare Advisors LLC now owns 48,354 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 427 shares during the period. Legal & General Group Plc increased its stake in shares of BioCryst Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 860 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of BioCryst Pharmaceuticals by 4.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,500 shares during the period. Finally, Nationwide Fund Advisors increased its stake in shares of BioCryst Pharmaceuticals by 4.5% in the 2nd quarter. Nationwide Fund Advisors now owns 46,149 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 1,975 shares during the period. 70.21% of the stock is owned by institutional investors.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.